2260959-53-1

Basic information

• Product Name: 5-bromo-7-fluoro-2,3-dihydro-1H-inden-4-amine
• CAS NO: 2260959-53-1
• Molecular Weight: 230.08
• Mol File: 2260959-53-1.mol

Chemical Properties

• CAS DataBase Reference: 5-bromo-7-fluoro-2,3-dihydro-1H-inden-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-7-fluoro-2,3-dihydro-1H-inden-4-amine(2260959-53-1)
• EPA Substance Registry System: 5-bromo-7-fluoro-2,3-dihydro-1H-inden-4-amine(2260959-53-1)

Safety Data

• Hazardous Substances Data: 2260959-53-1(Hazardous Substances Data)

Upstream product

• 2260959-52-0 7-fluoro-2,3-dihydro-1H-inden-4-amine 
• 2260959-50-8 7-fluoro-4-nitro-2,3-dihydro-1H-inden-1-ol 
• 651735-59-0 7-fluoro-2,3-dihydro-1H-inden-1-one 
• 1092347-71-1 7-fluoro-4-nitro-2,3-dihydro-1H-inden-1-one 

Downstream Products

• 2676863-53-7 7-fluoro-5-isopropyl-2,3-dihydro-1H-inden-4-amine 
• 2676863-29-7 5-cyclopropyl-7-fluoro-2,3-dihydro-1H-inden-4-amine 

Relevant articles and documents

SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS

Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.

NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS

The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R1 may optionally be substituted; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

NOVEL COMPOUNDS

The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic groups, wherein the hydrocarbyl group may optionally be substituted, and wherein the hydrocarbyl group may optionally include one or more heteroatoms N, O or S in its carbon skeleton; and R2 is a cyclic group substituted at the a-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

NOVEL COMPOUNDS

The present invention relates to substituted 5-membered nitrogen containing heteroaryl compounds, such as sulfonyl triazoles, where the heteroaryl ring is further substituted, optionally via a linking group such as -NH-, with a cyclic group which in turn is substituted at the α-position. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.